83570-42-7

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 1-(6-quinoxalinyl)(9CI) is used as an active pharmaceutical ingredient for the development of drugs targeting various medical conditions. Its unique chemical structure allows it to interact with biological targets, making it a promising candidate for drug discovery and therapeutic applications.
Used in Agricultural Industry:
Ethanone, 1-(6-quinoxalinyl)(9CI) is used as a chemical intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its unique properties enable it to be incorporated into these products, enhancing their effectiveness in controlling pests and weeds.
Used in Research:
Ethanone, 1-(6-quinoxalinyl)(9CI) is used as a research compound in various scientific studies. Its unique properties make it a valuable tool for understanding the mechanisms of chemical reactions and exploring new areas of chemical research.
It is important to handle Ethanone, 1-(6-quinoxalinyl)(9CI) with caution, as it can be hazardous if not properly managed. Its precise uses and properties depend on the specific application and the context in which it is being used.

Upstream product

• 1432-42-4 1-(4-amino-3-nitrophenyl)ethanone 
• 50998-17-9 6-bromoquinoxaline 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 131543-46-9 Glyoxal 
• 21304-39-2 1-(3,4-diaminophenyl)ethanone 
• 111-34-2 -butyl vinyl ether 
• 6925-00-4 quinoxaline-6-carboxylic acid 
• 875558-38-6 N-methoxy-N-methylquinoxaline-6-carboxamide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 874279-36-4 1-(quinoxalin-6-yl)ethan-1-ol 

Relevant academic research and scientific papers

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

FUSED GLYCOSIDASE INHIBITORS

Compounds of formula (I), wherein A, Z, E, R1, R2, m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Meta C-H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity

Controlling site selectivity of C-H activation without using a directing group remains a significant challenge. While Pd(II) catalysts modulated by a mutually repulsive pyridine-type ligand have been shown to favor the relatively electron-rich carbon centers of arenes, reversing the selectivity to favor palladation at the relatively electron-deficient positions has not been possible. Herein we report the first catalytic system that effectively performs meta C-H arylation of a variety of alkoxy aromatics including 2,3-dihydrobenzofuran and chromane with exclusive meta site selectivity, thus reversing the conventional site selectivity governed by native electronic effects. The identification of an effective ligand and modified norbornene (NBE-CO2Me), as well as taking advantage of the statistics, are essential for achieving the exclusive meta selectivity.

NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF

The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-β, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

LINEAR GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, L, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

ANTI-HCMV COMPOSITIONS AND METHODS

Novel compounds useful for treating and/or preventing HCMV infections are provided.

PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES

The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.